Airway ObstructionRRV AirwayNCT03733704
One Minute Heart Rate Variability Quantification in Airway Obstruction Model
A study testing Heart rate variability analysis in people with Airway Obstruction, run by Rambam Health Care Campus.
Trial summary
40 healthy volunteers underwent a trial of obstructed breathing through an eighteen cm long, four mm internal diameter tube. Heart rate was recorded during three consecutive sets comprised of one minute control followed by one minute of obstructed breathing, with one minute of rest between sets. Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Airway Obstruction
- What is being tested?
- Heart rate variability analysis
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- 20 May 2015to 1 Jul 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- 18 30 years old
- healthy
Who cannot join
- heart disease
- lung disease
- BMI > 26
- ECG abnormalities
About this study
40 healthy volunteers underwent a trial of obstructed breathing through an eighteen cm long, four mm internal diameter tube. Heart rate was recorded during three consecutive sets comprised of one minute control followed by one minute of obstructed breathing, with one minute of rest between sets. Time and frequency domain analysis were used to compare HRV during control versus obstructed breathing.
Read the detailed description
Following approval by the Institutional Review Board, the study was performed in a prospective cross-over, longitudinal cohort manner. Healthy volunteers aged between 20 and 40 years were included. Each participant signed an informed consent. Exclusion criteria were respiratory or cardiac pathology, diabetes, a body mass index lower than 18 or higher than 26 kg/m2, chronic medical conditions with significant involvement of the sympathetic or parasympathetic systems (e.g. diabetes), obstructive sleep apnea, use of medications with either cardiovascular or respiratory effects, and ECG abnormalities including heart rate other than sinus rhythm, atrioventricular conduction blocks, intrafascicular conduction delays or prolonged QT interval (the time between consecutive Q and T waves on the electrocardiogram).
Initially, each volunteer underwent an ultrasound evaluation (SonoSite™ M-Turbo™ ultrasound machine, SonoSite, Bothell, Washington, USA) of the lungs using a high frequency linear probe at mid clavicular lines to exclude pneumothorax, an apical view of the heart using a curve-linear probe to exclude pericardial effusion. A twelve lead ECG was obtained and analyzed to exclude rate or conduction abnormalities. Noninvasive blood pressure and oxygen saturation were recorded in all subjects throughout the study to identify and prevent any complication.
A three lead ECG and spirometry were obtained in supine position with the upper body raised by 30 degrees. Data was collected using a Datex AS/3 monitor (Datex Ohmeda Medical Equipment, GE Healthcare, USA). The data was recorded using a digital to analog acquisition card (NI-6008, National Instruments™, Austin, Texas, USA) and a Biosignal Logger of National Instruments™ Biomedical Workbench™ at a sampling rate of 500 Hertz (Hz). All experiments were performed at the same time of day (early afternoon), and under the same conditions (same place and experimental setup). Volunteers were instructed to refrain from smoking for 4 hours prior to participating in the study.
The airway obstruction was simulated by an 18 cm long, 4 mm internal diameter endotracheal tube, connected to a spirometry adaptor and an antimicrobial filter. During the obstructed breathing phase, the volunteers were directed to seal their lips tightly around the filter to prevent air leak and encouraged to reach a peak pressure of 30-40 cm H2O, using the instantaneous display on the spirometry monitor. Three sets were recorded for each volunteer; each set was comprised of one minute of normal unobstructed breathing that served as control, immediately followed by one minute of obstructed breathing. Following each set, the volunteers were allowed at least one minute of rest period to recover and return to their baseline breathing before the next set.
HRV analysis A detailed description of the means to measure and evaluate the significance of HRV can be found in the European Society of Cardiology and the North American Society of Pacing Electrophysiology Task Force on heart rate variability, standards of measurement and physiological interpretation and clinical use guidelines14. Briefly, the raw ECG signal was preprocessed (including high pass filtering to remove Baseline wandering and ECG feature identification) and the R-R intervals were extracted from the raw ECG signal using ECG Features Extractor of National Instruments™ Biomedical Workbench™ with threshold adjust factor of 0.1, a rough highest heart rate of 60 beats per minute, QRS frequency of 10-25 Hz and middle QRS onset and offset.
Evaluation of HRV is predominantly performed using time and frequency domains. It may be also performed using nonlinear methods; however, here the investigators concentrated on the more commonly used time and frequency domain methods. Time domain measures are based on the statistical analysis of the time interval between two adjacent QRS waves on the electrocardiogram complexes, referred to as R-R intervals (time between two consecutive R waves on the electrocardiogram). R-R intervals standard deviation (SD), root mean square of successive differences (RMSSD) between adjacent R-R intervals, number of pairs of successive R-R intervals that differ by more than 50 millisecond (NN50) and proportion of NN50 divided by total number of R-R intervals (pNN50) are routinely used to quantify HRV. Frequency domain employ mathematical manipulation to the signal, such as the fast Fourier transform (FFT), which converts the time function into a sum of sine waves of different frequencies. These are used to calculate the power spectral density in very low (VLF), low (LF) and high frequency (HF) ranges and provide a quantification of the physiological HRV-related effects. In this report the investigators did not include the VLF, as this value cannot be reliably measured with a brief measurement window of one minute. As HRV is clearly related to the heart rate, the investigators normalized the HF power and LF power to the heart rate15. The normalized values are referred to as HFnorm and LFnorm.
HRV parameters were calculated over one minute sampling window using the Heart Rate Variability Analyzer of National Instruments™ Biomedical Workbench™. Fast Fourier analysis was employed using a Hanning Window of 1024 samples with a 50% overlap, and with a 2 Hz interpolation rate and 1024 frequency bins. As suggested in the literature for the power spectral density calculation, HF was defined as 0.15-0.4 Hz, LF as 0.04-0.15 Hz and VLF as below 0.04 Hz14.
Respiratory rate calculation To evaluate the changes in respiration during the obstructed breathing the investigators calculated the respiratory rate during the control and obstructed breathing periods. the investigators used the raw ECG traces to calculate the respiratory rate16. This was done primarily based on the R wave amplitude, and calculating the number of local peaks in the sampling window. To obtain meaningful results the investigators chose the control and the obstructed breathing segments with the most obvious changes in the R wave amplitude. Using this methodology the investigators could reliably evaluate the respiratory rate in 33 subjects.
- Conditions
- Airway Obstruction
- Being tested
- Heart rate variability analysis
- Medical subject headings
- Airway Obstruction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Heart rate variability analysisDiagnostic test
Heart rate variability analysis extracted from ECG during normal and obstructed breathing
| Study group | Role | What they receive |
|---|---|---|
| Healthy volunteers | Experimental | Healthy volunteers Receives: Diagnostic Test: Heart rate variability analysis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Low Frequency Power Spectral Density
FFT HRV Low Frequency Power Spectral Density
Measured: 1 minute
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Nov 2018
- Study start20 May 2015
- Primary completion11 Jun 2015
- Study completion1 Jul 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Airway ObstructionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Spontaneous ventilation via an obstructing plastic tube
- Masking
- None (open label)
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rambam Health Care Campus
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Amit Lehavi MD FANZCA, Rambam Health Care Campus
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03733704
- Sponsor's protocol ID
- RRV Airway
- Acronym
- RRV Airway
- Status last verified
- Nov 2018
- First submitted
- 4 Nov 2018
- Last updated
- 8 Nov 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Lehavi A, Golomb N, Leiba R, Katz YS, Raz A. One-minute heart rate variability - an adjunct for airway obstruction identification. Physiol Rep. 2019 Jan;7(1):e13948. doi: 10.14814/phy2.13948.
PubMed 30632302
Study at a glance
From the registry record, last updated by the sponsor on 8 Nov 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- One Minute Heart Rate Variability Quantification in Airway Obstruction Model
- ClinicalTrials.gov ID
- NCT03733704
- Acronym / sponsor ID
- RRV Airway / RRV Airway
- Conditions
- Airway Obstruction
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Rambam Health Care CampusUniversity, hospital or other
- Study start
- 20 May 2015 (actual)
- Primary completion
- 11 Jun 2015 (actual)
- Study completion
- 1 Jul 2015 (actual)
- First posted
- 7 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
40 healthy volunteers underwent a trial of obstructed breathing through an eighteen cm long, four mm internal diameter tube. Heart rate was recorded during three consecutive sets comprised of one minute control followed by one minute of obstructed breathing, with one minute of rest between sets. Time and frequency domain analysis were used to compare HRV during control versus obstructed breathing.
Detailed description
Following approval by the Institutional Review Board, the study was performed in a prospective cross-over, longitudinal cohort manner. Healthy volunteers aged between 20 and 40 years were included. Each participant signed an informed consent. Exclusion criteria were respiratory or cardiac pathology, diabetes, a body mass index lower than 18 or higher than 26 kg/m2, chronic medical conditions with significant involvement of the sympathetic or parasympathetic systems (e.g. diabetes), obstructive sleep apnea, use of medications with either cardiovascular or respiratory effects, and ECG abnormalities including heart rate other than sinus rhythm, atrioventricular conduction blocks, intrafascicular conduction delays or prolonged QT interval (the time between consecutive Q and T waves on the electrocardiogram).
Initially, each volunteer underwent an ultrasound evaluation (SonoSite™ M-Turbo™ ultrasound machine, SonoSite, Bothell, Washington, USA) of the lungs using a high frequency linear probe at mid clavicular lines to exclude pneumothorax, an apical view of the heart using a curve-linear probe to exclude pericardial effusion. A twelve lead ECG was obtained and analyzed to exclude rate or conduction abnormalities. Noninvasive blood pressure and oxygen saturation were recorded in all subjects throughout the study to identify and prevent any complication.
A three lead ECG and spirometry were obtained in supine position with the upper body raised by 30 degrees. Data was collected using a Datex AS/3 monitor (Datex Ohmeda Medical Equipment, GE Healthcare, USA). The data was recorded using a digital to analog acquisition card (NI-6008, National Instruments™, Austin, Texas, USA) and a Biosignal Logger of National Instruments™ Biomedical Workbench™ at a sampling rate of 500 Hertz (Hz). All experiments were performed at the same time of day (early afternoon), and under the same conditions (same place and experimental setup). Volunteers were instructed to refrain from smoking for 4 hours prior to participating in the study.
The airway obstruction was simulated by an 18 cm long, 4 mm internal diameter endotracheal tube, connected to a spirometry adaptor and an antimicrobial filter. During the obstructed breathing phase, the volunteers were directed to seal their lips tightly around the filter to prevent air leak and encouraged to reach a peak pressure of 30-40 cm H2O, using the instantaneous display on the spirometry monitor. Three sets were recorded for each volunteer; each set was comprised of one minute of normal unobstructed breathing that served as control, immediately followed by one minute of obstructed breathing. Following each set, the volunteers were allowed at least one minute of rest period to recover and return to their baseline breathing before the next set.
HRV analysis A detailed description of the means to measure and evaluate the significance of HRV can be found in the European Society of Cardiology and the North American Society of Pacing Electrophysiology Task Force on heart rate variability, standards of measurement and physiological interpretation and clinical use guidelines14. Briefly, the raw ECG signal was preprocessed (including high pass filtering to remove Baseline wandering and ECG feature identification) and the R-R intervals were extracted from the raw ECG signal using ECG Features Extractor of National Instruments™ Biomedical Workbench™ with threshold adjust factor of 0.1, a rough highest heart rate of 60 beats per minute, QRS frequency of 10-25 Hz and middle QRS onset and offset.
Evaluation of HRV is predominantly performed using time and frequency domains. It may be also performed using nonlinear methods; however, here the investigators concentrated on the more commonly used time and frequency domain methods. Time domain measures are based on the statistical analysis of the time interval between two adjacent QRS waves on the electrocardiogram complexes, referred to as R-R intervals (time between two consecutive R waves on the electrocardiogram). R-R intervals standard deviation (SD), root mean square of successive differences (RMSSD) between adjacent R-R intervals, number of pairs of successive R-R intervals that differ by more than 50 millisecond (NN50) and proportion of NN50 divided by total number of R-R intervals (pNN50) are routinely used to quantify HRV. Frequency domain employ mathematical manipulation to the signal, such as the fast Fourier transform (FFT), which converts the time function into a sum of sine waves of different frequencies. These are used to calculate the power spectral density in very low (VLF), low (LF) and high frequency (HF) ranges and provide a quantification of the physiological HRV-related effects. In this report the investigators did not include the VLF, as this value cannot be reliably measured with a brief measurement window of one minute. As HRV is clearly related to the heart rate, the investigators normalized the HF power and LF power to the heart rate15. The normalized values are referred to as HFnorm and LFnorm.
HRV parameters were calculated over one minute sampling window using the Heart Rate Variability Analyzer of National Instruments™ Biomedical Workbench™. Fast Fourier analysis was employed using a Hanning Window of 1024 samples with a 50% overlap, and with a 2 Hz interpolation rate and 1024 frequency bins. As suggested in the literature for the power spectral density calculation, HF was defined as 0.15-0.4 Hz, LF as 0.04-0.15 Hz and VLF as below 0.04 Hz14.
Respiratory rate calculation To evaluate the changes in respiration during the obstructed breathing the investigators calculated the respiratory rate during the control and obstructed breathing periods. the investigators used the raw ECG traces to calculate the respiratory rate16. This was done primarily based on the R wave amplitude, and calculating the number of local peaks in the sampling window. To obtain meaningful results the investigators chose the control and the obstructed breathing segments with the most obvious changes in the R wave amplitude. Using this methodology the investigators could reliably evaluate the respiratory rate in 33 subjects.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Spontaneous ventilation via an obstructing plastic tube
| Arm | Type | Receives |
|---|---|---|
| Healthy volunteers | Experimental | Diagnostic Test: Heart rate variability analysisHealthy volunteers |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- 18 30 years old
- healthy
Key exclusion criteria (4 listed)
- heart disease
- lung disease
- BMI > 26
- ECG abnormalities
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Heart rate variability analysisHeart rate variability analysis extracted from ECG during normal and obstructed breathing | Diagnostic test | Healthy volunteers |
Primary outcome
Low Frequency Power Spectral Density
Time frame: 1 minute
FFT HRV Low Frequency Power Spectral Density
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Nov 2018.
- Derived from this study: PubMed 30632302Lehavi A, Golomb N, Leiba R, Katz YS, Raz A. One-minute heart rate variability - an adjunct for airway obstruction identification. Physiol Rep. 2019 Jan;7(1):e13948. doi: 10.14814/phy2.13948.
- Individual participant dataSharing planned: No
Related trials for Airway Obstruction
Recruiting
Measuring Nasal Airway Changes After VivAer Treatment Using AI Analysis
Nasal Airway Obstruction
Active, not recruitingObservational study
A Prospective Study Comparing VivAer to Alternative Surgical Procedures to Treat Nasal Airway Obstruction in Patients With Nasal Valve Dysfunction.
Nasal Airway Obstruction
Not yet recruiting
Pharyngeal Mucosal Conditioning to Prevent Postoperative Sore Throat in Septoplasty Patients With Severe Nasal Obstruction
Postoperative Sore Throat, Nasal Obstruction
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Not yet recruitingObservational study
Post-market Clinical Follow-up Study of an Isotonic Saline Solution for the Relief of Nasal Congestion in Infants and Toddlers
Nasal Congestion, Common Cold
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Heart rate variability analysis in people with Airway Obstruction, run by Rambam Health Care Campus.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Low Frequency Power Spectral Density (time frame: 1 minute). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03733704, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2018.